高风险初次膝或髋关节置换患者使用氨甲环酸不增加并发症:38,220例回顾性病例对照研究
该研究回顾性分析了2011至2017年在本机构接受初次全膝关节置换或全髋关节置换的38,220例患者(其中高风险8,877例),20,501例(54%)接受了静脉氨甲环酸。高风险患者中,接受与未接受氨甲环酸者90天血栓并发症、死亡及再入院的比值比无显著差异(OR 1.00,95%CI 0.85-1.18)。作者认为该结果不支持氨甲环酸在高风险关节置换患者中增加不良结局的担忧。
要点
- 高风险关节置换患者接受氨甲环酸后90天不良结局OR为1.00(95%CI 0.85-1.18)。
- 高风险患者中,接受氨甲环酸者90天DVT和PE的OR为0.84(95%CI 0.59-1.19)。
- 高风险患者中,接受氨甲环酸者90天MI和CVA的OR为0.91(95%CI 0.56-1.49)。
核心结论
- 高风险全膝关节置换和全髋关节置换患者接受氨甲环酸后,不良结局的比值比无统计学显著差异。
研究设计与样本
- 回顾性病例对照研究,纳入2011至2017年在本机构接受初次全膝关节置换或全髋关节置换的38,220例患者,其中高风险8,877例。
主要发现
- 高风险患者中,接受氨甲环酸者与未接受氨甲环酸者相比,90天血栓并发症、死亡及再入院的OR为1.00(95%CI 0.85-1.18)。
- 高风险患者中,接受氨甲环酸者与未接受氨甲环酸者相比,90天DVT和PE的OR为0.84(95%CI 0.59-1.19)。
- 高风险患者中,接受氨甲环酸者与未接受氨甲环酸者相比,90天MI和CVA的OR为0.91(95%CI 0.56-1.49)。
临床怎么用
- 作者认为,该研究为高风险初次关节置换患者使用氨甲环酸提供了增量证据支持,但未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tranexamic acid (TXA) administration to reduce postoperative blood loss and transfusion is a well-established practice for total knee arthroplasty (TKA) and total hip arthroplasty (THA). However, clinical concerns remain about the safety of TXA in patients with a history of a prothrombotic condition. We sought to determine the risk of complications between high-risk and low-risk TKA and THA patients receiving TXA. METHODS: We retrospectively reviewed 38,220 patients (8877 high-risk cases) who underwent primary TKA and THA between 2011 and 2017 at our institution. Intravenous TXA was administered in 20,501 (54%) of cases. The rates of thrombotic complications (deep vein thrombosis [DVT], pulmonary embolism [PE], myocardial infarction [MI], and cerebrovascular accident [CVA]) as well as mortality and readmission were assessed at 90 days postoperatively. Additionally, we evaluated 90-day postoperative occurrence of DVT and PE separate from occurrence of MI and CVA. Patients were categorized as high risk if they had a past medical history of a prothrombotic condition prior to surgery. RESULTS: There was no significant difference in the odds of these adverse outcomes between high-risk patients who received TXA and high-risk patients who did not receive TXA (odds ratio [OR] 1.00, 95% confidence interval [CI] 0.85-1.18). There were also no differences when evaluating the odds of 90-day postoperative DVT and PE (OR 0.84, 95% CI 0.59-1.19) nor MI and CVA (OR 0.91, 95% CI 0.56-1.49) for high-risk patients receiving TXA vs high-risk patients who did not receive TXA. CONCLUSION: TXA administration to high-risk TKA and THA patients is not associated with a statistically significant difference in adverse outcomes. We present incremental evidence in support of TXA administration for high-risk patients undergoing primary arthroplasties.
引用
- Porter SB, White LJ, Osagiede O, et al. Tranexamic Acid Administration Is Not Associated With an Increase in Complications in High-Risk Patients Undergoing Primary Total Knee or Total Hip Arthroplasty: A Retrospective Case-Control Study of 38,220 Patients. J Arthroplasty. 2019. PMID: 31522854. doi:10.1016/j.arth.2019.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。